Prepared by Regenerative Medicine China · Public sources checked 20 September 2026. Patient information, not an individual medical recommendation.
What is EBV-targeted mRNA cancer therapy?
Therapeutic mRNA vaccines provide instructions for cells to make selected antigens, with the aim of stimulating an immune response. This is a treatment research approach for people with cancer, distinct from preventive vaccination. NCI explains the mRNA approach.
On 3 June 2026, West China Hospital reported implementation of an EBV-antigen-specific mRNA tumour treatment technique at Hainan Haikong Lecheng Hospital (West China Lecheng Hospital). The report identifies EBV-related tumours, including lymphoma and nasopharyngeal cancer. Read the hospital report.
A hospital report and a registered trial are different evidence
Two relevant ClinicalTrials.gov records were checked on 20 September 2026:
- NCT05714748: phase I EBV mRNA immunotherapy research in refractory EBV-positive malignancies; registry status Active, not recruiting.
- NCT07028047: phase I evaluation of WGc-043 in advanced EBV-positive solid tumours; registry status Not yet recruiting.
Registry status may change and may lag the study site. Neither record confirms an open appointment in Lecheng. We do not assume that a registered study and a local clinical-application programme share the same product specification, criteria, schedule or fee. A trial authorisation is not the same as general marketing approval.
Early-phase research focuses on questions such as safety, dose and preliminary activity. It cannot provide a reliable personal cure or survival forecast. Ask for published results relevant to your diagnosis and the exact protocol being proposed.
What does an EBV-related cancer review need?
Send the pathology diagnosis and any tumour EBV testing already performed, such as an EBER report if available. Include EBV DNA results if your treating team has requested them. Ask the reviewing oncologist which tissue or blood tests the proposed protocol actually requires; do not arrange extra tests solely from an online checklist.
Prior infection or a positive antibody test alone is not an oncology eligibility decision. The registered studies apply cancer-specific and general health criteria, including prior treatment, functional status and organ function. These research criteria must not be substituted for the current Lecheng programme’s written requirements.
Request the protocol’s risk information, monitoring schedule, precautions and plan for unexpected reactions. Neither “mRNA” nor “vaccine” means risk-free, and uncertain benefit should be part of informed consent.
Hospital review before travel
RMC coordinates information and communication; we do not make treatment decisions. Naming a hospital in a source does not establish a partnership or an appointment channel. Read how we verify institutions and our five-gate verification process.
- Confirm the exact product or procedure, hospital, indication and applicable regulatory route.
- Ask the institution to confirm current international-patient intake and the documents required for review.
- Obtain an individual eligibility decision, written risks and an itemised quotation before paying or travelling.
Records to prepare for an oncology review
- Pathology report, cancer type, stage and date of diagnosis.
- A dated treatment timeline: surgery, radiotherapy, chemotherapy, targeted medicines and immunotherapy, including response and reasons for stopping.
- Recent imaging reports, relevant biomarker results and your oncologist’s summary.
- Current medicines, significant illnesses and the question you want a specialist to answer.
Start with a short summary and selected reports. Our form accepts up to 3 PDF/JPEG/PNG files, 5 MB each and 10 MB combined. Do not send passport copies or large imaging archives at this stage. See medical-record preparation.
What should a cancer therapy quotation include?
We have not verified a current, patient-specific international-patient price for these pathways. A per-injection figure is not a complete treatment budget. Ask for separate charges for specialist review, pathology or biomarker tests, cell collection or manufacture where relevant, medicines, administration, admission, adverse-event care and follow-up.
Also clarify cancellation terms if you are ineligible or a product cannot be prepared, which research costs are covered by a sponsor, and which travel, interpreting and accommodation costs are excluded. Do not apply stem-cell cost estimates to an oncology protocol. Clinical-trial participation is not a treatment package.
Plan the China journey after the clinical decision
Keep your treating oncologist involved. Do not delay or stop an existing treatment plan to pursue an unconfirmed option. Before travel, establish the expected visit schedule, need for admission, what happens if treatment is unsuitable, and who will manage complications or follow-up after you return home. See the international patient guide.
Questions patients ask
Does a positive EBV test mean I should receive this therapy?
No. The tumour diagnosis, the type of EBV test and the proposed protocol need specialist review. This page does not establish a cancer diagnosis or treatment eligibility.
Is WGc-043 currently recruiting through RMC?
RMC is not a trial sponsor or recruitment site. The two cited registry records were not recruiting on the date checked; current access must be confirmed with the relevant institution.
Does a Lecheng announcement mean approval throughout China?
Do not generalise a local programme announcement into nationwide marketing approval. Ask for the exact regulatory route and approved or authorised scope of the proposed treatment.
Sources and verification limits
- West China Hospital: EBV mRNA implementation report, 3 June 2026
- ClinicalTrials.gov NCT05714748
- ClinicalTrials.gov NCT07028047
- NCI: how mRNA vaccines might help treat cancer
Primary institutional and registry sources are linked above. We have not independently confirmed international-patient intake, a current quotation or an RMC partnership with the named institutions. Public-source checking is not clinical peer review.